Equities

Avacta Group PLC

AVCT:LSE

Avacta Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)49.00
  • Today's Change2.50 / 5.38%
  • Shares traded2.24m
  • 1 Year change-61.72%
  • Beta1.8128
Data delayed at least 20 minutes, as of Nov 22 2024 17:05 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform1
Hold0
Sell1
Strong Sell0

Share price forecast

The 3 analysts offering 12 month price targets for Avacta Group Plc have a median target of 99.00, with a high estimate of 100.00 and a low estimate of 40.00. The median estimate represents a 102.04% increase from the last price of 49.00.
High115.1%100.00
Med112.9%99.00
Low-14.0%40.00

Earnings history & estimates

Avacta Group Plc reported annual 2023 losses of -7.48 per share on Apr 30, 2024.
Average growth rate+0.04%
More ▼

Revenue history & estimates

Avacta Group Plc had revenues for the full year 2023 of 23.25m. This was 140.83% above the prior year's results.
Average growth rate+84.53%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.